Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers.
Colorectal cancer
IHC
PHD1
Tissue microarray
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
18
02
2023
accepted:
19
03
2023
medline:
31
7
2023
pubmed:
29
3
2023
entrez:
28
3
2023
Statut:
ppublish
Résumé
Prolyl hydroxylase 1 (PHD1) is a prognostic marker in several cancers. This study was undertaken to elucidate the clinical relevance of PHD1 in colorectal cancer (CRC) prognosis. We compared PHD1 expression on a tissue microarray (TMA) containing samples from 1800 CRCs with corresponding clinicopathological tumor variables and patient survival. While PHD1 staining was always high in benign colorectal epithelium, high PHD1 staining was detectable in only 71.8% of CRCs. Low PHD1 staining was associated with advanced tumor stage (p = 0.0101) and shortened overall survival in CRC patients (p = 0.0011). In a multivariable analysis including tumor stage, histological type and PHD1 staining revealed tumor stage and histological type (p < 0.0001 each), but also PHD1 staining (p = 0.0202) to be independent prognostic markers for CRC. In our cohort, loss of PHD1 expression independently identified a subset of CRC patients with poor overall survival and might, thus, be a promising prognostic marker. PHD1 targeting may even allow for specific therapeutic approaches for these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Prolyl hydroxylase 1 (PHD1) is a prognostic marker in several cancers.
AIMS AND SCOPES
UNASSIGNED
This study was undertaken to elucidate the clinical relevance of PHD1 in colorectal cancer (CRC) prognosis.
MATERIALS AND METHODS
METHODS
We compared PHD1 expression on a tissue microarray (TMA) containing samples from 1800 CRCs with corresponding clinicopathological tumor variables and patient survival.
RESULTS
RESULTS
While PHD1 staining was always high in benign colorectal epithelium, high PHD1 staining was detectable in only 71.8% of CRCs. Low PHD1 staining was associated with advanced tumor stage (p = 0.0101) and shortened overall survival in CRC patients (p = 0.0011). In a multivariable analysis including tumor stage, histological type and PHD1 staining revealed tumor stage and histological type (p < 0.0001 each), but also PHD1 staining (p = 0.0202) to be independent prognostic markers for CRC.
CONCLUSIONS
CONCLUSIONS
In our cohort, loss of PHD1 expression independently identified a subset of CRC patients with poor overall survival and might, thus, be a promising prognostic marker. PHD1 targeting may even allow for specific therapeutic approaches for these patients.
Identifiants
pubmed: 36976352
doi: 10.1007/s00432-023-04717-y
pii: 10.1007/s00432-023-04717-y
pmc: PMC10374750
doi:
Substances chimiques
Prolyl Hydroxylases
EC 1.14.11.-
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7579-7585Informations de copyright
© 2023. The Author(s).
Références
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
Exp Mol Pathol. 2013 Jun;94(3):453-7
pubmed: 23531419
J Cell Mol Med. 2010 Apr;14(4):758-70
pubmed: 20178464
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Cancer Genet. 2014 May;207(5):188-94
pubmed: 24935227
PLoS One. 2011;6(8):e23847
pubmed: 21887331
Science. 2001 Nov 9;294(5545):1337-40
pubmed: 11598268
Science. 2001 Apr 20;292(5516):468-72
pubmed: 11292861
Clin Cancer Res. 2008 Oct 15;14(20):6634-9
pubmed: 18927305
Exp Biol Med (Maywood). 2012 Jul;237(7):860-6
pubmed: 22802519
Anticancer Res. 2018 Jan;38(1):329-336
pubmed: 29277791
Cancer Res. 2003 Dec 15;63(24):8777-83
pubmed: 14695194
Cancer Lett. 2008 Apr 8;262(1):87-93
pubmed: 18187257
BMC Cancer. 2013 Nov 06;13:526
pubmed: 24195777
Am J Pathol. 2010 May;176(5):2292-301
pubmed: 20363910
J Biol Chem. 1995 Jan 20;270(3):1230-7
pubmed: 7836384
Nat Rev Cancer. 2002 Jan;2(1):38-47
pubmed: 11902584
EMBO Mol Med. 2015 Aug 19;7(10):1350-65
pubmed: 26290450
J Clin Pathol. 2016 Mar;69(3):209-14
pubmed: 26281861
Oncogene. 2002 Jan 24;21(5):836-43
pubmed: 11850811
Science. 2001 Apr 20;292(5516):464-8
pubmed: 11292862
Cancer Cell. 2009 Nov 6;16(5):413-24
pubmed: 19878873
Z Gastroenterol. 2010 Jan;48(1):65-136
pubmed: 20072998
Virchows Arch. 2014 Jun;464(6):645-54
pubmed: 24711168
Histopathology. 2010 Jun;56(7):908-20
pubmed: 20497244
Gastroenterology. 2010 Feb;138(2):606-15
pubmed: 19786027